Peregrine holds out for survival data as tepid Phase II PFS in NSCLC vexes market
This article was originally published in Scrip
Executive Summary
The market reacted negatively to an inconsistent result within Phase II data reported by Peregrine Pharmaceuticals for its first-in-class phosphatidylserine inhibitor, bavituximab, in front-line non-small cell lung cancer (NSCLC).